CytoSorbents Expanding Marketing Reach Of CytoSorb Blood Purifier
This article was originally published in Clinica
Executive Summary
CytoSorbents is sponsoring the REFRESH I trial of its CytoSorb extracorporeal cytokine adsorber in the US, which the company hopes will support approval of a pivotal trial of the device for reducing reduce plasma free hemoglobin and cytokines in patients undergoing complex cardiac surgery.
You may also be interested in...
Clinical Corner: New Data From Xeltis Bioabsorbable Heart Repair Devices Headlines Trial News
Medtech Insight's Clinical Corner highlights recent R&D news and developments in ongoing clinical trials of early, late-stage and approved medical devices. This installment includes news on Abbott's Xience drug-eluting coronary stents, Xeltis' bioabsorbable devices for congenital heart defects, NeuroMetrix's Quell pain therapy, and CytoSorbents' blood purifier to treat inflammation in surgery patients.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.
New’s We’re Watching: J&J's Varipulse PFA Earns CE Mark; Labs Create Intravascular Robots; And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, Biosense Webster’s Varipulse PFA platform earned a CE mark; Biosense Webster also announced the start the pivotal IDE study of its Laminar left atrial appendage elimination system; the FDA approved Boston Scientific's Agent paclitaxel-coated balloon and cleared Medtronic's OsteoCool 2.0 bone ablation system; three papers in Science Robotics describe magnetically controlled vascular robots that could go places wires and catheters cannot.